Zealand Pharma A/S (Zealand Pharma A/S) ROCE % : -59.24% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zealand Pharma A/S's annualized ROCE % for the quarter that ended in Dec. 2023 was -59.24%.

Zealand Pharma A/S ROCE % Historical Data

The historical data trend for Zealand Pharma A/S's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S ROCE % Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-45.88

-50.81

-46.49

-57.33

-45.54

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-112.47	-58.25	-82.62	16.09	-59.24

Zealand Pharma A/S ROCE % Calculation

Zealand Pharma A/S's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-100.073	/	( ( (219.255 - 27.836)	+	(289.693 - 41.637) )	/ 2 )
	=	-100.073	/	( (191.419	+	248.056)	/ 2 )
	=	-100.073	/	219.7375
	=	-45.54 %

Zealand Pharma A/S's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-154.764	/	( ( (311.333 - 36.868)	+	(289.693 - 41.637) )	/ 2 )
	=	-154.764	/	( ( 274.465	+	248.056 )	/ 2 )
	=	-154.764	/	261.2605
	=	-59.24 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Zealand Pharma A/S (OTCPK:ZLDPF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zealand Pharma A/S ROCE % Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.